CD4 and AIDS: Many factors affect the incidence of adverse drug reactions, but the most significant ones were a decrease lower CD4 cell count, advanced WHO HIV/AIDS clinical stages, not taking opportunistic infection prophylaxis, a Tenofovir (TDF)–Nevirapine (NVP) containing regimen, being bedridden at the time of treatment initiation, and concurrent treatment administration [17–20].